
Acerux250 mg/via
Opsonin Pharma Ltd.

IV Infusion
What is Xovir 250 mg/vial used for?
Xovir 250 mg/vial cream is a herpes simplex virus (HSV) nucleoside analogue DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.
What is the dosage of Xovir 250 mg/vial?
Xovir 250 mg/vial cream should be applied five times per day for four days. Therapy should be initiated as early as possible following the onset of signs or symptoms of herpes labialis i.e., during the prodrome or when lesions appear. For adolescents 12 years of age and older, the dosage is the same as in adults.
What are the side effects of Xovir 250 mg/vial?
The most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving Xovir 250 mg/vial cream and placebo. Three patients on Xovir 250 mg/vial cream and one patient on placebo discontinued treatment due to a…
Who should not take Xovir 250 mg/vial?
Xovir 250 mg/vial cream is contraindicated in patients with known hypersensitivity to Xovir 250 mg/vial, valXovir 250 mg/vial, or any component of the formulation.
What precautions should be taken with Xovir 250 mg/vial?
Xovir 250 mg/vial cream should only be applied on the affected external aspects of the lips and face in patients with herpes labialis. Because no data are available, application to human mucous membranes is not recommended. Xovir 250 mg/vial cream is intended for cutaneous use only and should not be used in the eye or inside the mouth or nose. Cream has a potential for irritation and contact. The …
Is Xovir 250 mg/vial safe during pregnancy and breastfeeding?
Pregnancy Category B. There are no adequate and well-controlled studies of Xovir 250 mg/vial cream in pregnant women. Xovir 250 mg/vial cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether topically applied Xovir 250 mg/vial is excreted in breast milk. Systemic exposure following topical administration is minimal.
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.